Studies on CBD and Schizophrenia reveal more expansive treatment options
Endocannabinoid professionals are learning more about CBD and schizophrenia. Multiple CBD trials for schizophrenia have demonstrated that different types of cannabinoids are able to treat symptoms of schizophrenia, reducing the frequency of psychotic episodes.
Here are 12 case studies documenting the benefit of CBD treatment for schizophrenia.
Medical professionals have identified that certain enzymes work to synthesize cannabinoids and endocannabinoids – maximizing their benefit. At the same time, certain enzymes degrade cannabinoids and endocannabinoids, minimizing their efficacy. Patients with schizophrenia have higher levels of endocannabinoid-degrading enzymes and lower levels of endocannabinoid synthesizing enzymes.
A group of psychiatric professionals in Spain conducted research involving CBD and schizophrenia. (https://www.ncbi.nlm.nih.gov/pubmed/23822951)
In this study, they recognized that CBD worked with the endocannabinoid system to produce two vital endocannabinoid-synthesizing enzymes. They are: NAPE (N- acyl phosphatidylethanolamine phospholipase) and DAGL (diacylglycerol lipase). They reverse the endocannabinoid deficiency and thereby minimize the psychotic symptoms of schizophrenia.
But that’s not all!
CBD treatment for schizophrenia also works by inhibiting the production of CBD-degrading enzymes. Two of these chief offenders are FAAH (fatty acid amide hydrolase) and MAGL (monoacylglycerol lipase).
Therefore, CBD oil for schizophrenia is even more effective in restoring positive activity in the endocannabinoid system.
A clinical trial conducted on CBD and schizophrenia in the United Kingdom proves cannabinoids effectively and safely treat schizophrenia.
A group of researchers in the UK conducted a CBD trial for schizophrenia. (https://www.ncbi.nlm.nih.gov/pubmed/29241357)
In this study, scientists compared schizophrenic patients receiving CBD to those receiving a placebo. Not surprisingly, patients receiving CBD treatment for schizophrenia showed fewer psychotic symptoms.
CBD trials for schizophrenia prove that cannabinoids help to reduce the frequency of psychotic episodes.
Scientists in Germany conducted research involving CBD and schizophrenia. (https://www.ncbi.nlm.nih.gov/pubmed/22716153)
More specifically, they compared CBD treatment for schizophrenia to a previously released endocannabinoid system antagonist. Researchers reported that cannabinoids out-performed this synthetic version that a Hempuralist can only compare to FDA approved pharmaceuticals.
A study on CBD and schizophrenia with rats showed that CBD effectively improved social activity. Furthermore CBD treatment for schizophrenia resulted in enhanced recognition and working memory.
Scientists in Australia conducted a study involving CBD treatment for schizophrenia. (https://www.ncbi.nlm.nih.gov/pubmed/28230072)
For the rationale of this study, they stated that patients with schizophrenia often suffer from learning disabilities. Primarily, this is due to cognitive impairment and is expressed through attention and memory deficits. By using CBD to address these developmental roadblocks, the progression of schizophrenia can at least be slowed – if not arrested altogether.
Studies on CBD and schizophrenia make it clear that CBD has antipsychotic properties.
A group of neurologists in Brazil presented facts about the non-psychoactive properties of CBD and schizophrenia symptoms it treats. (https://www.ncbi.nlm.nih.gov/pubmed/16612464)
They mentioned that previous CBD trials for schizophrenia on both animals and humans have revealed CBD’s ability to manage psychotic symptoms. They also referenced other psychiatric conditions. For example, they mentioned that CBD oil for bipolar disorder had also proven to be an effective treatment.
Other endocannabinoid professionals from around the world are also referencing multiple studies involving CBD and schizophrenia.
Brain experts and psychiatrists from the United Kingdom and the Netherlands collaborated on research involving CBD and schizophrenia. They identified multiple studies on Medline and EMBASE in which professionals tested the safety and efficacy of CBD treatment for schizophrenia, both in vivo and in vitro. Additionally, researchers performed CBD trials for schizophrenia on both animals and humans.
Scientists are learning more about using CBD to signal anandamide production – an endocannabinoid our brains produce.
Since experts learned about the existence of the endocannabinoid system, they’ve been identifying cannabinoids that are not only found in cannabis, but that are also endogenous to our bodies. Endocannabinoid professionals call these ‘endocannabinoids’. Our brains produce endocannabinoids naturally, and they affect a variety of physiological and psychological functions.
Psychiatrists have been learning more about the impact that anandamide has on mood. The more anandamide our bodies produce, the more stable our moods become.
Scientists in Germany conducted a study involving CBD and schizophrenia. (https://www.ncbi.nlm.nih.gov/pubmed/22832859)
In this study, they focused on anandamide signaling with CBD. They reported that it successfully alleviated many of the psychotic symptoms experts associate with schizophrenia.
Some experts are referring to the unpredictable, psychoactive properties of THC in order to make the point that CBD treatment for schizophrenia is not only non-mind-altering, it also counteracts the psychedelic effects of THC.
The key point is that CBD is a non-psychoactive alternative. Furthermore, endocannabinoid professionals have proven that THC has therapeutic benefits – despite its psychedelic nature. Given that, when THC is combined with CBD treatments for schizophrenia, it may provide some benefit. That’s especially true considering that CBD reduces the ‘high’ associated with THC. Therefore, if CBD treatments are supplemented with low levels of THC, the benefits outweigh any potential downsides.
This was backed up by other documentation related to CBD and schizophrenia.
A team of psychiatrists and neuroscientists in the Netherlands documented that hemp reduced the frequency of psychotic experiences due to its high CBD count. (https://www.ncbi.nlm.nih.gov/pubmed/21592732)
Researchers compared the effects of increasing the amount of CBD content compared to THC among avid smokers. They identified that higher CBD counts alleviated psychotic experiences more profoundly. They mentioned specifically that this was valuable research in identifying CBD treatments for schizophrenia.
Research on CBD and schizophrenia shows that cannabinoids regulate the mesolimbic dopamine system by modulating activity in the 5-HT1A receptor.
A group of addiction research specialists in Canada presented information related to CBD treatment for schizophrenia. (https://www.ncbi.nlm.nih.gov/pubmed/28185872)
Here, they acknowledged the positive impact that CBD had on activity in the 5-HT1A receptor. Endocannabinoid professionals and psychiatrists alike have already identified this receptor as not only being responsible psychological health, but also being susceptible to mediation via the endocannabinoid system. Like many other researchers, this group of professionals indicated that cannabis can treat the cognitive challenges presented by schizophrenia.
Many are concerned about the dangerous side effects associated with FDA-approved, prescription, anti-psychotic drugs. With this in mind, endocannabinoid professionals believe that endocannabinoid signaling with CBD could present new therapies for schizophrenia and other psychotic conditions.
Endocannabinoid professionals from GW Pharmaceuticals Cannabinoid Research Institute released information about the benefit of endocannabinoid signaling over traditional, pharmaceutical anti-psychotics. (https://www.ncbi.nlm.nih.gov/pubmed/23829368)
From enhancing reward processing in the brain to regulating healthy sleep patterns, CBD for schizophrenia treats multiple symptoms aside from those directly related to psychosis.
30 years of scientific investigation has proven that CBD is an effective antipsychotic. Not only that, like many other studies, research on CBD and schizophrenia have proven time and time again that cannabinoids are safe and that patients tolerate them well.
A group of professionals in Brazil presented documentation of a long history of research involving the endocannabinoid system, CBD, and schizophrenia. (https://www.ncbi.nlm.nih.gov/pubmed/22716160)
In this documentation, they noted that CBD treatments for schizophrenia have proven to be both effective and safe.
Similar to many other diseases hemp CBD products treat, experts across the globe conducting research on CBD an schizophrenia agree that the safety and efficacy of cannabis warrant the development of CBD treatments for schizophrenia.